Table 3.
Clinical trials of edaravone in ALS patients (data source ClinicalTrials.gov).
| Clinical Trials Involving Edaravone Study Title | Status | Identification Code |
|---|---|---|
| Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients with ALS | Completed | NCT00424463 |
| Efficacy and Safety Study of MCI-186 for Treatment of ALS | Completed | NCT00330681 |
| Safety Extension Study of Oral Edaravone Administered in Subjects with ALS | Recruiting | NCT04577404 |
| Efficacy and Safety Study of MCI-186 for Treatment of ALS who Met Severity Classification III | Completed | NCT00415519 |
| Phase 3 Study of MCI-186 for Treatment of ALS | Completed | NCT01492686 |
| Biomarkers in Different Types of ALS Patients Being Treated with Edaravone | Recruiting | NCT04097158 |
| Treatment Effect of Edaravone in Patients with ALS | Active, not recruiting | NCT03272802 |
| Radicava® (Edaravone) Findings in Biomarkers From ALS | Recruiting | NCT04259255 |
| Clinical Pharmacology Study of Oral Edaravone in Patients with ALS | Completed | NCT04176224 |
| Clinical Pharmacology Study of Oral Edaravone in ALS Patients with Gastrostomy | Completed | NCT04254913 |
| The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS | Not yet recruiting | NCT04391361 |
| Efficacy and Safety Study of Oral Edaravone Administered in Subjects with ALS | Recruiting | NCT04569084 |